International Clinical Trial: Safety and Efficacy of BiTE in Desensitization Therapy for Highly Sensitized Kidney Transplant Candidates with cPRA >= 90%

Geneva, Aug. 17 -- International Clinical Trials Registry received information related to the study (ChiCTR2600129635) titled 'Safety and Efficacy of BiTE in Desensitization Therapy for Highly Sensitized Kidney Transplant Candidates with cPRA >= 90%' on Aug. 7.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: West China Hospital of Sichuan University

Condition: Patients with end-stage renal disease (ESRD) who require kidney transplantation but are ineligible for transplant surgery due to refractory highly sensitized HLA antibodies, and who have failed first- and second-line therapies.

Intervention: Bispecific T cell engager treatment group1:Blinatumomab group:BiTE (CD19 x CD3 Bispecific Antibody)

Recruitme...